Digital therapeutics and mental health
Big Health's SleepioRx FDA-approved in August 2024
TDP worked with Big Health to achieve a 10% increase in engagement for their Sleepio app, helping them take a meaningful step toward their goals.
Big Health aimed to help people improve their sleeping habits by updating their Sleepio app to make it more user-friendly. Their focus was on encouraging users to complete daily sleep diaries, which could play a key role in improving remission rates for those dealing with sleep issues.
Big Health, a digital therapeutics company with $75M Series C funding (top investor: Softbank) sought to improve Sleepio, its insomnia therapy app. While 76% of users reported better sleep after six weeks, boosting sleep diary engagement was key to higher success rates.
We redesigned the app to enhance usability and encourage consistent diary entries, driving better outcomes and helping more users achieve remission from insomnia.
We created the sleep diary with intuitive multiple-choice questions and developed a clear, actionable data dashboard with a branded UI. This made Sleepio more engaging and rewarding, designing the ultimate tool for improving sleep outcomes.
9/10 Sleepio users would now recommend the app to others after the TDP redesign
83% of users in the test completed the redesigned questionnaire due to its improved user-friendliness and engagement. As a result, the Sleepio app achieved a perfect 10/10 NPS for questionnaire completion, boosting the likelihood of users recommending Big Health. The intuitive new UI enhances engagement, reinforcing Big Health's dedication to user well-being and promising user growth.